Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono
Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor. The update provides a closer look at the hand Merck is holding as it gears up to fight Daiichi Sankyo and Ono Pharmaceutical for the tenosynovial giant cell tumor market.
Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor. The update provides a closer look at the hand Merck is holding as it gears up to fight Daiichi Sankyo and Ono Pharmaceutical for the tenosynovial giant cell tumor market.
